证券代码：300214 证券简称：日科化学 公告编号：2026-007 山东日科化学股份有限公司 关于持股5%以上股东减持计划的预披露公告 1、减持原因：个人资金需求。 股东赵东日先生保证向本公司提供的信息内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 持有本公司股份 61,338,778 股（占公司总股本的 13.19%，占公司剔除回购 专用账户股份后总股本的 13.63%）的股东赵东日先生，计划通过集中竞价交易、 大宗交易的方式减持公司股份不超过 13,498,000 股（占公司总股本的 3%，占公 司剔除回购专用账户股份后总股本的 3%）。 山东日科化学股份有限公司（以下简称"公司"）近日收到股东赵东日先生 的《关于股份减持计划的告知函》，赵东日先生计划通过集中竞价交易、大宗交 易的方式减持公司股份不超过 13,498,000 股，即不超过公司总股本的 3%。现将 有关情况公告如下： | 股东姓名 | 无限售条件股份 | 有限售条件股份 | | 持股总数（股） | 持股总数占公司剔除 回购专用账户股份后 | | ...

北京德和衡（济南）律师事务所 关于山东日科化学股份有限公司 2026 年第一次临时股东会的法律意见书 二〇二六年二月 北京德和衡（济南）律师事务所 关于山东日科化学股份有限公司 2026 年第一次临时股东会的法律意见书 德和衡证见意见（2026）第00011号 致：山东日科化学股份有限公司 北京德和衡（济南）律师事务所（简称"本所"）接受山东日科化学股份有限 公司（简称"公司"）的委托，指派张霞律师、王圣然律师出席了公司 2026 年第 一次临时股东会（简称"本次股东会"），并出具本法律意见书。 本所律师根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中 华人民共和国公司法》（以下简称"《公司法》"）、《上市公司股东会规则》《深 圳证券交易所创业板股票上市规则（2025 年修订）》（以下简称"《创业板股票 上市规则》"）、《深圳证券交易所上市公司股东会网络投票实施细则（2025 年 修订）》（以下简称"《网络投票实施细则》"）等法律、法规和规范性文件以及 《山东日科化学股份有限公司章程》（以下简称"《公司章程》"）的规定，就本 次股东会的召集和召开程序、会议召集人和出席会议人员的资格、会议表决程序 ...

证券代码：300214 证券简称：日科化学 公告编号：2026-006 山东日科化学股份有限公司 2026 年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现否决议案的情形； 2、本次股东会没有涉及变更前次股东会决议。 一、会议召开和出席情况 1、召开时间： 现场会议时间：2026年2月6日下午14:30 网络投票时间： 3、召开方式：本次股东会采取现场投票与网络投票相结合的方式召开。 4、会议召集人：公司第六届董事会。 5、主持人：董事长田志龙先生。 6、会议的出席情况 （1）本次会议出席的股东及股东代理人147人，代表股份19,821,312股，占 公司股份总数的4.2635%。其中，出席现场会议的股东1人，代表股份709,400股， 占公司股份总数的0.1526%；通过网络投票的股东146人，代表股份19,111,912股， 占公司股份总数的4.1109%。 （2）出席本次股东会的股东及股东代理人中，中小投资者147人，代表股份 19,821,312股，占公司股份总数的4.2635%。 "中小投资 ...

Core Viewpoint - The company emphasizes that all operational decisions and investment strategies are based on industry development trends and long-term strategic planning, ensuring compliance with internal and external decision-making processes and information disclosure obligations [2] Group 1 - The management aims for sustainable development and maximization of shareholder interests, focusing on steady operations and continuous enhancement of the company's intrinsic and market value [2]

Core Viewpoint - The company emphasizes its commitment to rigorous research and decision-making processes in project layout and advancement, ensuring compliance with review and disclosure procedures to protect shareholder interests [2]. Group 1 - The company states that its project layout and advancement follow a strict research process and complete decision-making process [2]. - Major investment decisions are made in accordance with standardized review processes and information disclosure procedures [2]. - The company focuses on its core business to enhance operational quality and safeguard the legitimate rights and interests of all shareholders [2].

证券日报网讯2月4日，日科化学（300214）在互动平台回答投资者提问时表示，公司已按照《深圳证券 交易所创业板股票上市规则》完成了2025年度业绩预告，详情请查阅公司公告。 ...

Core Viewpoint - Guoen Technology Co., Ltd. officially listed on the Hong Kong Stock Exchange on February 4, with an initial offering price of HKD 36 per share, opening at HKD 45, a 25% increase, and a total market capitalization of approximately HKD 135 billion [1] Company Overview - Guoen Technology specializes in new chemical materials and upstream and downstream products of gelatin and collagen, serving the chemical and health industries [4][5] - The company was founded in 2000 by Wang Aiguo in Qingdao and has developed into a vertically integrated industrial cluster over more than 20 years [5][7] Financial Performance - Revenue projections for Guoen Technology are as follows: RMB 134 billion for 2022, RMB 174.4 billion for 2023, and RMB 191.9 billion for 2024, with net profits of RMB 7.2 billion, RMB 5.4 billion, and RMB 7.2 billion respectively [5][6] - For the first three quarters of 2025, the company reported revenue of RMB 154.97 billion and a net profit of RMB 7.21 billion [5] Business Segments - The company operates in two main segments: the large chemical segment, which accounts for approximately 95.6% of revenue, and the large health segment, which accounts for about 4.4% [6][7] - In the large chemical sector, Guoen Technology has established three main business engines: green petrochemical new materials, organic polymer modified materials, and organic polymer composite materials [7] IPO Details - The IPO saw a subscription rate of 2,251.85 times for the public offering, with 300,000 shares allocated, representing 10% of the total offering [4] - The international placement received a subscription rate of 10.03 times, with 27 million shares allocated, accounting for 90% of the total offering [4] Future Plans - Proceeds from the IPO will be used to establish a new production base in Thailand to expand capacity, produce organic polymer modified materials, and set up a regional headquarters to support international market expansion [8]

Group 1 - The company, 日科化学, has announced an earnings forecast indicating a net profit loss attributable to shareholders of the listed company ranging from 18 million to 30 million yuan for 2025 [1] - In comparison, the net profit attributable to shareholders for the same period last year was a loss of 68.16 million yuan [1]

日科化学公告，预计2025年度净利润为负，预计归属于上市公司股东的净利润为-1800万元至-3000万 元，上年同期为-6816.12万元。预计扣除非经常性损益后的净利润为-2400万元至-3600万元，上年同期 为-7026.74万元。预计营业收入为37亿元至39亿元，上年同期为35.18亿元。预计扣除后营业收入为 36.65亿元至38.65亿元，上年同期为34.78亿元。 ...

Financial Projections - The estimated net profit for 2025 is projected to be between -30 million and -18 million CNY, compared to -68.16 million CNY in the same period last year[3] - Operating revenue is expected to reach between 370 million and 390 million CNY, an increase from 351.84 million CNY in the previous year[3] - The company anticipates a significant improvement in operating performance, with a projected total profit ranging from a loss of 5.9 million to a profit of 8.22 million CNY, compared to a loss of 90.99 million CNY last year[5] - The impact of non-recurring gains and losses on net profit is estimated to be around 6 million CNY, up from 2.11 million CNY in the previous year[6] - In the first three quarters of 2025, the net profit attributable to shareholders is reported to be positive[6] - The specific data for the 2025 annual performance will be disclosed in the annual report[7] Cost Management Strategies - The company has implemented cost reduction and efficiency enhancement strategies, including expanding the supplier system and optimizing production processes[5] Tax Implications - The company’s subsidiary obtained high-tech enterprise status in December 2025, leading to a change in applicable corporate income tax rates and an adjustment of deferred income tax expenses totaling approximately 31 million CNY[6]